24091588
Results 1 to 1 of 1
Selection :
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsBLACK, Mark D; STEVENS, Rachel J; ARAD, Michal et al.Psychopharmacologia. 2011, Vol 215, Num 1, pp 149-163, issn 0033-3158, 15 p.Article
